Clinical trials
NSCLC Stage IIIB clinical trials
Below are recruiting nsclc stage iiib clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07039656RecruitingPhase 2
Toripalimab plus chemo after NSCLC surgery
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Guangzhou, GuangdongAges 18–75 - NCT05286957RecruitingPhase 2
MRD-guided immunotherapy plus chemo after lung cancer surgery
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
Zhengzhou, HenanAges 18–80 - NCT05991206Recruiting
Atezolizumab with chemo before surgery for lung cancer
This study tests a combination of the immunotherapy drug atezolizumab with standard chemotherapy given before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Changsha, HunanAges 18 years+ - NCT06864624RecruitingPhase 2
Perioperative sunvozertinib for stage II-IIIB NSCLC with EGFR exon 20 insertion
This trial tests the drug sunvozertinib before and after surgery for non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). It aims to see if the drug can help shrink tumors and improve outcomes for patients whose cancer is at stage II, IIIA, or IIIB.
Changsha, HunanAges 18 years+ - NCT04865250RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
Heidelberg, BaWüAges 18 years+ - NCT04892953RecruitingPhase 2
Durvalumab plus focused radiation for progressing stage III lung cancer
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
Houston, TexasAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT06939127RecruitingPhase 2
Cold therapy, immunotherapy, and chemo before and after lung cancer surgery
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
TianjinAges 18–75 - NCT07016126RecruitingPhase 3
Study of D-BACE, chemo, and carlizumab for lung cancer
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07410975RecruitingPhase 2
Immunotherapy and chemo before surgery for lung cancer
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07010419RecruitingPhase 3
Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+ - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06241807RecruitingPhase 2
Camrelizumab plus chemo before surgery for stage III lung cancer
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
Jinan, ShandongAges 18–75 - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT07153445RecruitingPhase 2
Atezolizumab before and after surgery for stage III lung cancer
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
Alicante, AlicanteAges 18 years+ - NCT06918132RecruitingPhase 2
Cemiplimab and Fianlimab before lung cancer surgery
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
Rochester, MinnesotaAges 18 years+ - NCT06167460Recruiting
Blood test to monitor targeted therapy response in advanced lung cancer
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
Ho Chi Minh CityAges 18–80 - NCT03948100Recruiting
Yoga coaching for lung or esophageal cancer during radiation
This study tests whether a guided yoga program helps people with lung or esophageal cancer improve strength, daily functioning, and quality of life while they receive radiation therapy. It also involves a family caregiver, to support the patient during treatment.
Houston, TexasAges 18 years+ - NCT04789681RecruitingPhase 2
Canakinumab to prevent lung cancer from persistent lung nodules
This trial tests canakinumab to lower the risk of lung cancer growing from persistent lung nodules seen on CT scans. It may help people at higher risk who have either never had lung cancer or had early lung cancer treated in the past.
Houston, TexasAges 18 years+
Hear when a new NSCLC Stage IIIB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc stage iiib?
- Yes. Clin2 currently lists 59 recruiting nsclc stage iiib studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc stage iiib trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc stage iiib trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.